$FBLG

FibroBiologics issued a $1.2M convertible debenture to Peak One, including 125,000 commitment shares. The debenture, sold at a 15% discount, has 0% interest but converts at $0.78/share if default occurs, with up to 18% interest and 120% acceleration. The company can redeem at par in 2027 if no default happens, with Nasdaq rules limiting ownership and share exchange. Proceeds from future financings or asset sales may repay the debenture.

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 7, 2026, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Peak One Opportunity Fund, L.P. (“Peak One”), pursuant to which the Company agreed to issue to Peak One, in

FibroBiologics Inc. (FBLG) filed a U.S. patent for a cell-based platform that produces therapeutic peptides continuously in the body, potentially replacing GLP-1 injections for weight loss and diabetes. The technology targets multiple conditions and uses various cell types. Shares were down 1.28% premarket.

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer HOUSTON, September 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the “Company”), a clinical-stage biotechnology company with 270+ pate

FibroBiologics (FBLG) raised $500,000 via a private placement to its Chief Scientific Officer, including 298,508 shares and warrants. The offering price was $1.675 per share and warrant, matching the Nasdaq closing price plus a premium. Proceeds will be used for general corporate purposes. The warrants are exercisable immediately and expire in five years.

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 15, 2026, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Hamid Khoja, Ph.D., the Company’s Chief Scientific Officer (the “Purchaser”), relating to the issuance a

FibroBiologics (FBLG) received a U.S. patent for its fibroblast-based wound healing therapy. Preclinical studies showed faster healing, including in diabetic models. The stock is down 9.74% to $1.76.

FibroBiologics (FBLG) shipped a new batch of its experimental drug CYWC628 to Australia for a clinical trial on diabetic foot ulcers. The Phase 1/2 study evaluates safety, tolerability, and efficacy of the treatment. The company expects to report interim data in late 2026, with preclinical data suggesting potential for accelerated wound healing. FibroBiologics focuses on treatments for chronic diseases using fibroblast cells.

FibroBiologics (Nasdaq: FBLG) reported that its preclinical study showed cartilage repair in degenerative joints within four weeks of a single injection of chondrocyte spheroids. The company claims the therapy could offer a less invasive, lower-cost alternative to joint replacement, with a rapid four-day manufacturing process. FibroBiologics holds over 270 patents in various clinical pathways, including orthopedics.

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 FibroBiologics Appoints Leigh Steinberg to Board of Directors Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board HOUSTON, August 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a c